Along this line, upregulated expression of ADAM17 and/or overexpression of ADAM10 has been associated with tumor progression as well as poor prognosis of numerous human cancers, e.g., gastric, colon, breast, pancreatic and lung cancer and hepatocellular carcinoma (for review see [39,41,43]). Here, ADAM10 is linked to neoplasm.